These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8437635)
1. [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome]. Van Hout BA; Rutten FF; Lorijn RH Ned Tijdschr Geneeskd; 1993 Feb; 137(7):360-4. PubMed ID: 8437635 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of HA-1A treatment for patients with sepsis. van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376 [TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients]. Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. Schulman KA; Glick HA; Rubin H; Eisenberg JM JAMA; 1991 Dec; 266(24):3466-71. PubMed ID: 1744962 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. Chalfin DB; Holbein ME; Fein AM; Carlon GC JAMA; 1993 Jan; 269(2):249-54. PubMed ID: 8417245 [TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo]. Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633 [TBL] [Abstract][Full Text] [Related]
7. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827 [TBL] [Abstract][Full Text] [Related]
8. The economic impact of HA-1A (Centoxin) against endotoxin. Barriere SL Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053 [TBL] [Abstract][Full Text] [Related]
9. [A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis]. Badía X; Segú L; García Alonso F; Rovira J Med Clin (Barc); 1993 Jan; 100(3):84-9. PubMed ID: 8426499 [TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602 [TBL] [Abstract][Full Text] [Related]
11. HA-1A in septic patients with ARDS: results from the pivotal trial. Bigatello LM; Greene RE; Sprung CL; Panacek EA; Straube RC; Zimmerman JL; Maunder RJ; Lanken PN; Pile-Spellmann E; Stanek KS Intensive Care Med; 1994 May; 20(5):328-34. PubMed ID: 7930026 [TBL] [Abstract][Full Text] [Related]
12. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Barriere SL; Guglielmo BJ Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812 [TBL] [Abstract][Full Text] [Related]
13. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. Linden PK; Angus DC; Chelluri L; Branch RA J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965 [TBL] [Abstract][Full Text] [Related]
14. The economic impact and cost-effectiveness of monoclonal antibody therapy for sepsis. Chalfin DB; Fein AM Clin Infect Dis; 1993 Nov; 17 Suppl 2():S520-4. PubMed ID: 8274619 [TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of biologic therapies for plaque psoriasis. Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ; Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016 [TBL] [Abstract][Full Text] [Related]